TLSI insider buying and SEC filings, explained
TriSalus Life Sciences, Inc. · CIK 1826667
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$3.6M
Insiders who bought
6
Sold (not marked 10b5-1)
$140K
Planned sales (10b5-1)
$0
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 5, 2026 | Sale | Bryan F. Cox (Chief of Research) sold 296 shares at $4.39 ($1K). Holdings down <1% to 162,805 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 7, 2026, 4:02 PM ET |
| Oct 5, 2026 | Sale | Richard Marshak (Chief Commercial Officer) sold 325 shares at $4.39 ($1K). Holdings down <1% to 127,994 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 7, 2026, 4:02 PM ET |
| Oct 5, 2026 | Sale | Jennifer Stevens (Chief Regulatory Officer) sold 316 shares at $4.39 ($1K). Holdings down <1% to 123,794 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Oct 7, 2026, 4:02 PM ET |
| May 15, 2026 | Sale | Richard Marshak (Chief Commercial Officer) sold 543 shares at $2.67 ($1K). Holdings down <1% to 125,101 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 19, 2026 |
| May 15, 2026 | Purchase (code P) | Mats Wahlstrom (Director) bought 60,000 shares at about $2.53 ($152K), reported as a purchase (code P). Holdings up 69% to 147,555 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 18, 2026 |
| May 15, 2026 | Purchase (code P) | Michael P Stansky (Director) bought 610,000 shares directly and indirectly (by entity) at about $2.50 ($1.5M), reported as a purchase (code P). Direct holdings up 49% to 1,240,722 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 18, 2026 |
| May 15, 2026 | Purchase (code P) | Mary T Szela (CEO and Director) bought 39,682 shares at about $2.59 ($103K), reported as a purchase (code P). Holdings up 4% to 1,065,215 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 18, 2026 |
| May 15, 2026 | Purchase (code P) | David Patience (CFO) bought 7,100 shares at $2.43 ($17K), reported as a purchase (code P). Holdings up 3% to 275,757 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 18, 2026 |
| May 15, 2026 | Purchase (code P) | Gary B. Gordon (Director) bought 10,000 shares at $2.46 ($25K), reported as a purchase (code P). Holdings up 16% to 72,510 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 18, 2026 |
| Mar 11–16, 2026 | Sale | Jodi Devlin (Chief of Clinical Operations) sold 3,207 shares between Mar 11 and Mar 16 at about $4.11 ($13K). Holdings down 3% to 97,364 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 20, 2026 |
| Mar 11–16, 2026 | Sale | Bryan F. Cox (Chief of Research) sold 3,184 shares between Mar 11 and Mar 16 at about $4.11 ($13K). Holdings down 2% to 163,415 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 20, 2026 |
| Mar 11–16, 2026 | Sale | Richard Marshak (Chief Commercial Officer) sold 3,457 shares between Mar 11 and Mar 16 at about $4.11 ($14K). Holdings down 3% to 110,397 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 20, 2026 |
| Mar 11–16, 2026 | Sale | Jennifer Stevens (Chief Regulatory Officer) sold 3,530 shares between Mar 11 and Mar 16 at about $4.11 ($15K). Holdings down 3% to 124,110 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 20, 2026 |
| Mar 11–17, 2026 | Sale | Mary T Szela (CEO and Director) sold 20,302 shares between Mar 11 and Mar 17 at about $3.91 ($79K). Holdings down 3% to 752,987 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 20, 2026 |
| Feb 23, 2026 | Purchase (code P) | David Patience (CFO) bought 3,657 shares at $4.10 ($15K), reported as a purchase (code P). Holdings up 1% to 268,657 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 23, 2026 | Purchase (code P) | Gary B. Gordon (Director) bought 9,756 shares at $4.10 ($40K), reported as a purchase (code P). New position of 9,756 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 23, 2026 | Purchase (code P) | William Valle (Director) bought 30,487 shares at $4.10 ($125K), reported as a purchase (code P). New position of 30,487 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 23, 2026 | Purchase (code P) | Mary T Szela (CEO and Director) bought 30,487 shares at $4.10 ($125K), reported as a purchase (code P). Holdings up 4% to 773,289 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
| Feb 23, 2026 | Purchase (code P) | Michael P Stansky (Director) bought 361,098 shares directly and indirectly (by entity) at $4.10 ($1.5M), reported as a purchase (code P). Direct holdings up 45% to 787,132 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 23, 2026 |
22 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
5 insiders bought in 30 days
$1.8M in purchases since May 15, 2026 · Purchases traded May 15, 2026 to May 15, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Gary B. Gordon (Director) | $25K | May 15, 2026 | SEC filing |
| David Patience (CFO) | $17K | May 15, 2026 | SEC filing |
| Mary T Szela (CEO) | $103K | May 15, 2026 | SEC filing |
| Michael P Stansky (Director) | $1.5M | May 15, 2026 | SEC filing |
| Mats Wahlstrom (Director) | $152K | May 15, 2026 | SEC filing |
5 insiders bought in 30 days
$1.8M in purchases since Feb 23, 2026 · Purchases traded Feb 23, 2026 to Feb 23, 2026 · Closed
| Insider | Value | Traded | Source |
|---|---|---|---|
| Michael P Stansky (Director) | $1.5M | Feb 23, 2026 | SEC filing |
| Mary T Szela (CEO) | $125K | Feb 23, 2026 | SEC filing |
| William Valle (Director) | $125K | Feb 23, 2026 | SEC filing |
| Gary B. Gordon (Director) | $40K | Feb 23, 2026 | SEC filing |
| David Patience (CFO) | $15K | Feb 23, 2026 | SEC filing |
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow TLSI in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.